1. 1081PMolecular analysis of NRAS, BRAF, C-KIT, ROS1, ALK and RET alterations in serial biopsies in sinonasal mucosal melanoma. (23rd October 2018) Authors: Anguera Palacios, G; del Carpio, L P; Molina, M-A; Aguado, C; Gras-Cabrerizo, J R; Leon, X; Gonzalez-Cao, M; Karachaliou, N; Mozos, A; Gonzalez, A; Barnadas, A; Rosell, R; Majem, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1562PDMagnitude of clinical benefit of cancer drugs approved based on single-arm trials (SAT) by the US Food and Drug Administration (FDA). (23rd October 2018) Authors: Molto Valiente, C; Borrell, M; Ocana Fernandez, A; Templeton, A J; del Carpio, L P; Del Paggio, J; Barnadas, A; Booth, C M; Tibau, A; Amir, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1563PDMagnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval. (23rd October 2018) Authors: Borrell Puy, M; Molto Valiente, C; Vokinger, K; Hwang, T; Ocana Fernandez, A; Templeton, A J; Seruga, B; Gich Saladich, I; Barnadas, A; Amir, E; Tibau, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 1564PDMagnitude of clinical benefit of trials supporting US Food and Drug Administration (FDA) approval of breakthrough and non-breakthrough drugs. (23rd October 2018) Authors: Molto Valiente, C; Borrell, M; Hwang, T; Gich Saladich, I; Barnadas, A; Amir, E; Kesselheim, A; Tibau, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗